Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

BACKGROUND: Alectinib, a highly selective, central nervous system (CNS)-active anaplastic lymphoma kinase (ALK) inhibitor, demonstrated promising clinical activity in crizotinib-naïve and crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC). This phase 2 study evaluated the safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, Alice T., Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J., Cetnar, Jeremy, West, Howard, Camidge, D. Ross, Socinski, Mark A., Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H., Borghaei, Hossein, Gold, Kathryn A., Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ignatius Ou, Sai-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752892/
https://www.ncbi.nlm.nih.gov/pubmed/26708155
http://dx.doi.org/10.1016/S1470-2045(15)00488-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752892/
https://www.ncbi.nlm.nih.gov/pubmed/26708155
http://dx.doi.org/10.1016/S1470-2045(15)00488-X

Ejemplares similares